Dr. Friedlander on Checkpoint Inhibitors in the Second-Line Setting of Bladder Cancer

Terence Friedlander, MD
Published: Wednesday, Nov 29, 2017



Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.

The cleanest data is for pembrolizumab (Keytruda) from the KEYNOTE-045 study because there was an overall survival (OS) benefit independent of PD-L1 expression, explains Friedlander.

According to Friedlander, there is rationale to give atezolizumab (Tecentriq) in this setting when looking at the intent-to-treat population.
 


Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.

The cleanest data is for pembrolizumab (Keytruda) from the KEYNOTE-045 study because there was an overall survival (OS) benefit independent of PD-L1 expression, explains Friedlander.

According to Friedlander, there is rationale to give atezolizumab (Tecentriq) in this setting when looking at the intent-to-treat population.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x